Answers are grounded in this paper and cite their sources.
Advances in precision medicine have expanded access to targeted therapies and demand for molecular profiling of cholangiocarcinoma (CCA) patients in routine clinical practice. However, pathologists face challenges in establishing a definitive intrahepatic CCA (iCCA) diagnosis while preserving sufficient tissue for molecular profiling. Additionally, they frequently face challenges in optimal tissue handling to preserve nucleic acid integrity.
No takes yet. Share an insight, caveat, or question.
Evans et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: